127 related articles for article (PubMed ID: 7536091)
41. Physician, affective, and cognitive variables differentially predict 'initiation' versus 'maintenance' PSA screening profiles in diverse groups of men.
Consedine NS; Christie MA; Neugut AI
Br J Health Psychol; 2009 May; 14(Pt 2):303-22. PubMed ID: 18808732
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
Schröder FH; van der Maas P; Beemsterboer P; Kruger AB; Hoedemaeker R; Rietbergen J; Kranse R
J Natl Cancer Inst; 1998 Dec; 90(23):1817-23. PubMed ID: 9839522
[TBL] [Abstract][Full Text] [Related]
43. What should men know about prostate-specific antigen screening before giving informed consent?
Chan EC; Sulmasy DP
Am J Med; 1998 Oct; 105(4):266-74. PubMed ID: 9809686
[TBL] [Abstract][Full Text] [Related]
44. Formative evaluation of the prostate cancer screening practices of African-American physicians.
Stroud L; Ross LE; Rose SW
J Natl Med Assoc; 2006 Oct; 98(10):1637-43. PubMed ID: 17052055
[TBL] [Abstract][Full Text] [Related]
45. Prostate cancer. When to offer screening in the primary care setting.
Gambert SR
Geriatrics; 2001 Jan; 56(1):22-6, 29-31. PubMed ID: 11196336
[TBL] [Abstract][Full Text] [Related]
46. Does evidence-based information about screening for prostate cancer enhance consumer decision-making? A randomised controlled trial.
Gattellari M; Ward JE
J Med Screen; 2003; 10(1):27-39. PubMed ID: 12790313
[TBL] [Abstract][Full Text] [Related]
47. [Estimating standard performance measures of opportunistic screening for prostate cancer].
Leoni M; Falcini F; Ravaioli A; Foca F; Andalò G; Benini F; Dal Pozzo C; Ricci R; Naldoni C; Bucchi L
Epidemiol Prev; 2008; 32(6):285-93. PubMed ID: 19353962
[TBL] [Abstract][Full Text] [Related]
48. Demographics and health-related factors of men receiving prostate-specific antigen screening in Utah.
Merrill RM
Prev Med; 2001 Dec; 33(6):646-52. PubMed ID: 11716662
[TBL] [Abstract][Full Text] [Related]
49. Factors influencing primary care physicians' decision to order prostate-specific antigen (PSA) test for men without prostate cancer.
Hayat Roshanai A; Nordin K; Berglund G
Acta Oncol; 2013 Nov; 52(8):1602-8. PubMed ID: 23421929
[TBL] [Abstract][Full Text] [Related]
50. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening.
Catalona WJ; Smith DS; Ratliff TL; Basler JW
JAMA; 1993 Aug; 270(8):948-54. PubMed ID: 7688438
[TBL] [Abstract][Full Text] [Related]
51. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
Pron G
Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
[TBL] [Abstract][Full Text] [Related]
52. [Use of prostatic specific antigen in primary care (PSA)].
Panach-Navarrete J; Gironés-Montagud A; Sánchez-Cano E; Doménech-Pérez C; Martínez-Jabaloyas JM
Semergen; 2017 Apr; 43(3):189-195. PubMed ID: 27344583
[TBL] [Abstract][Full Text] [Related]
53. The effectiveness of screening for prostate cancer: a nested case-control study.
Concato J; Wells CK; Horwitz RI; Penson D; Fincke G; Berlowitz DR; Froehlich G; Blake D; Vickers MA; Gehr GA; Raheb NH; Sullivan G; Peduzzi P
Arch Intern Med; 2006 Jan; 166(1):38-43. PubMed ID: 16401808
[TBL] [Abstract][Full Text] [Related]
54. Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices.
Perez TY; Danzig MR; Ghandour RA; Badani KK; Benson MC; McKiernan JM
Urology; 2015 Jan; 85(1):85-9. PubMed ID: 25440819
[TBL] [Abstract][Full Text] [Related]
55. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
[TBL] [Abstract][Full Text] [Related]
56. Discrepancies between guidelines and clinical practice regarding prostate-specific antigen testing.
Hamoen EH; Reukers DF; Numans ME; Barentsz JO; Witjes JA; Rovers MM
Fam Pract; 2013 Dec; 30(6):648-54. PubMed ID: 24107269
[TBL] [Abstract][Full Text] [Related]
57. The validity of male patients' self-reports regarding prostate cancer screening.
Jordan TR; Price JH; King KA; Masyk T; Bedell AW
Prev Med; 1999 Mar; 28(3):297-303. PubMed ID: 10072749
[TBL] [Abstract][Full Text] [Related]
58. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
Catalona WJ; Smith DS; Ornstein DK
JAMA; 1997 May; 277(18):1452-5. PubMed ID: 9145717
[TBL] [Abstract][Full Text] [Related]
59. [Examination of serum prostate specific antigen (PSA) in the mass screening for prostatic diseases].
Kato M; Okada K
Hinyokika Kiyo; 1993 Mar; 39(3):221-3. PubMed ID: 7685140
[TBL] [Abstract][Full Text] [Related]
60. Lack of follow-up of prostate-specific antigen test results.
McFall SL; Smith DW
Public Health Rep; 2009; 124(5):718-25. PubMed ID: 19753950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
